Loss of estrogen receptor beta expression in follicular thyroid carcinoma predicts poor outcome

Thyroid

Volumn 23, Issue 4, 2013, Pages 456-465

  Heikkilä, Annukka ^a   Hagström, Jaana ^a   Mäenpää, Hanna ^b   Louhimo, Johanna ^b   Siironen, Päivi ^b   Heiskanen, Ilkka ^b   Haglund, Caj ^a,b   Arola, Johanna ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID FOLLICULAR CARCINOMA; TISSUE MICROARRAY; TUMOR CLASSIFICATION;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875726201     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0363     Document Type: Article

References (40)

1. DeLellis RA, Williams ED 2004 Thyroid and parathyroid tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) WHO Pathology & Genetics Tumours of Endocrine Organs, 4th edition. IARC Press, Lyon, pp 51-56.
2. Chan JKC, Hirokawa M, Evans H, Williams ED, Osamura Y, Cady B, Sobrinho-Simoes M, Derwahl M, Paschke R, Belge G, Oriola J, Studer H 2004 Follicular adenoma. In: DeLellis RA, Lloyd RV, Philipp UH, Eng C (eds) WHO Pathology & Genetics Tumours of Endocrine Organs, 4th edition. IARC Press, Lyon, pp 98-103.
3. Delbridge L 2006 Solitary thyroid nodule: current management. ANZ J Surg 76:381-386.
4. Sobrinho-Simoes M, Asa SL, Kroll TG, Nikiforov YE, DeLellis RA, Farid P, Kitamura Y 2004 Follicular carcinoma. In: DeLellis RA, Lloyd RV, Philipp UH, Eng C (eds) WHO Pathology & Genetics Tumours of Endocrine Organs, 4th edition. IARC Press, Lyon, pp 67-72.
5. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, Zettinig G, Niederle B 2004 Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocr Relat Cancer 11:131-139.
6. Mosselman S, Polman J, Dijkema R 1996 ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53.
7. Thomas C, Gustafsson JA 2011 The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597-608.
8. Satake M, Sawai H, Go VL, Satake K, Reber HA, Hines OJ, Eibl G 2006 Estrogen receptors in pancreatic tumors. Pancreas 33:119-127.
9. Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S, Iwase H 2001 Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 163:207-212.
10. Brandenberger AW, Tee MK, Jaffe RB 1998 Estrogen receptor alpha (ER-Alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83:1025-1028.
11. Rossi V, Bellastella G, De Rosa C, Abbondanza C, Visconti D, Maione L, Chieffi P, Della Ragione F, Prezioso D, De Bellis A, Bellastella A, Sinisi AA 2011 Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor alpha and beta. J Cell Physiol 226: 1334-1339.
12. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y, Ogawa J 2005 Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11:5084-5089.
13. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW 2000 Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 60:245-248.
14. Egawa C, Miyoshi Y, Iwao K, Shiba E, Noguchi S 2001 Quantitative analysis of estrogen receptor-Alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology 61:293-298.
15. Kawabata W, Suzuki T, Moriya T, Fujimori K, Naganuma H, Inoue S, Kinouchi Y, Kameyama K, Takami H, Shimosegawa T, Sasano H 2003 Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions. Mod Pathol 16:437-444.
16. Chen GG, Vlantis AC, Zeng Q, van Hasselt CA 2008 Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 8:367- 377.
17. Vaiman M, Olevson Y, Habler L, Kessler A, Zehavi S, Sandbank J 2010 Diagnostic value of estrogen receptors in thyroid lesions. Med Sci Monit 16:BR203- BR207.
18. Ali S, Coombes RC 2000 Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5:271-281.
19. Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M, Dietel M, Lage H, Surowiak P 2011 Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 17:511-518.
20. Halon A, Nowak-Markwitz E, Maciejczyk A, Pudelko M, Gansukh T, Gyorffy B, Donizy P, Murawa D, Matkowski R, Spaczynski M, Lage H, Surowiak P 2011 Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res 31:711-718.
21. Mauro LV, Dalurzo M, Carlini MJ, Smith D, Nunez M, Simian M, Lastiri J, Vasallo B, Bal de Kier Joffe E, Pallotta MG, Puricelli L 2010 Estrogen receptor beta and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer. Oncol Rep 24:1331-1338.
22. Heikkila A, Siironen P, Hagstrom J, Heiskanen I, Sankila R, Louhimo J, Haglund C, Arola J 2010 Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy. APMIS 118:846-854.
23. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M 2008 Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Hum Pathol 39:1656-1663.
24. Kholova I, Ryska A, Ludvikova M, Cap J, Pecen L 2003 Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology 14:27-31.
25. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M 2005 Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12:305-317.
26. Ludvikova M, Holubec L Jr, Ryska A, Topolcan O 2005 Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-A immunostaining. Anticancer Res 25:1835-1840.
27. Haynik DM, Prayson RA 2005 Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid. Arch Pathol Lab Med 129:736-741.
28. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML 1999 Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 23:678-685.
29. Magri F, Capelli V, Rotondi M, Leporati P, La Manna L, Ruggiero R, Malovini A, Bellazzi R, Villani L, Chiovato L 2012 Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient's risk. Endocr Relat Cancer 19:463-471.
30. Gustafsson JA, Warner M 2000 Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 74:245-248.
31. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M 2001 Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 86:1072-1077.
32. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P 2004 Loss of ERbeta expression as a common step in estrogendependent tumor progression. Endocr Relat Cancer 11:537-551.
33. Zeng Q, Chen GG, Vlantis AC, van Hasselt CA 2007 Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif 40:921-935.
34. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, Tiwari RK 2010 Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 20:33-41.
35. Zeng Q, Chen G, Vlantis A, Tse G, van Hasselt C 2008 The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J Pathol 214:425-433.
36. Moretti F, Nanni S, Pontecorvi A 2000 Molecular pathogenesis of thyroid nodules and cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14:517-539.
37. Tzen C, Huang Y, Fu Y 2003 Is atypical follicular adenoma of the thyroid a preinvasive malignancy? Hum Pathol 34:666-669.
38. Sobrinho-Simoes M, Albores-Saavedra J, Tallini G, Santoro M, Volante M, Pilotti S, Carcangiu ML, Papotti M, Matias- Guiu X, Guiter GE, Zakowski M, Sakamoto A 2004 Poorly differentiated carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) WHO Pathology & Genetics Tumours of Endocrine Organs, 4th edition. IARC Press, Lyon, pp 73-76.
39. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, Papotti M, Bussolati G, Lloyd RV 2010 Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol 23:1269-1278.
40. Ringel MD 2011 Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid 21:487-492.